Assembly Biosciences Inc (ASMB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$36.60+1.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ASMB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -2.5% |
| Our one-year growth estimate | diamond | 2.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 4.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ASMB — debt issuance
Dated 2026-05-26
Entry into a Material Definitive Agreement. On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto (the "Underwriters"), in connection with the issuance and sale, in an underwritten, registered offering (the "Offering"), of: (1) 3,358,602 shares (the "Offering Sha…
Why it matters: This study looks at ABI-6250 for cholestatic liver diseases. Good results could increase the product's market potential.
Supportive ifThe Phase 2 basket study for ABI-6250 begins as planned in Q1 2027.
Worry ifThe Phase 2 basket study is delayed beyond Q1 2027.
Why it matters: If healthcare revenue growth speeds up, it could benefit Assembly Biosciences and its peers.
Supportive ifHealthcare revenue growth speeds up to 10% or more each year.
Worry ifHealthcare revenue growth keeps slowing down below current levels.
Why it matters: The bonus plan affects how well the company keeps talent. Updates show how well management is doing.
Supportive ifManagement says they have started the 2026 Corporate Bonus Plan.
Worry ifManagement says the Corporate Bonus Plan had big delays or problems.
Why it matters: This plan will guide Assembly Bio's decision on the herpesvirus program. It could impact future revenue and partnerships.
Watch forGilead has a clear plan and budget for the herpesvirus program.
Also watch forGilead fails to provide a development plan or budget by mid-2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$196 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $548 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,218 loss on $10,000 · 42.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The cash position impacts Assembly Bio's ability to fund operations and clinical trials. A strong cash position supports growth plans.
Supportive ifAssembly Bio has over $200 million in cash after the stock offering.
Worry ifCash drops below $200 million after the offering.
Why it matters: Good results could show these candidates work and help further development. Bad results may hurt future chances.
Watch forAssembly Bio shares good results from the Phase 1b studies for ABI-5366 and ABI-1179.
Also watch forResults from the Phase 1b studies are disappointing or inconclusive.
Why it matters: The company needs to maintain cash to fund operations. A strong cash position is crucial for stability.
Supportive ifManagement says cash reserves are more than $50 million.
Worry ifManagement says cash reserves are less than $30 million.
Why it matters: The stock offering will help fund clinical development. Watching cash levels shows if the company can keep running.
Worry ifCash and cash equivalents stay above $200 million after the stock offering ends.
Less concerning ifCash and cash equivalents drop below $200 million after the offering ends.
Why it matters: This plan will help Assembly Bio decide on the herpesvirus program's cost and profit.
Watch forGilead's development plan is accepted. Assembly Bio joins the cost and profit share.
Also watch forGilead's development plan is not received by mid-2026 or Assembly Bio opts out.
Why it matters: Starting this study would show progress in treating unmet needs in liver diseases. It could boost investor confidence in the pipeline.
Supportive ifThe Phase 2 study for ABI-6250 in cholestatic liver diseases starts as planned in Q1 2027.
Worry ifThe Phase 2 study does not start on time or is delayed beyond Q1 2027.
Why it matters: This decision impacts future revenue sharing and could affect cash flow. It signals confidence in the herpesvirus program.
Supportive ifAssembly Bio joins the U.S. cost-profit share for the herpesvirus program. They got Gilead's cost estimates.
Worry ifAssembly Bio chooses not to join, showing worries about the program's success.
Why it matters: This study is important for better treatments for hepatitis delta virus. It could prove the company's pipeline.
Supportive ifThe Phase 2 study for ABI-6250 in HDV starts as planned by the end of 2026.
Worry ifThe Phase 2 study does not start on time or is delayed beyond 2026.
Why it matters: This payment helps fund operations. It also supports the company's financial health. It shows that the collaboration is working well.
Supportive ifAssembly Bio gets the $75 million payment from Gilead as planned in Q4 2026.
Worry ifThe payment is late or missing. This raises concerns about the collaboration.